Characterization of Bietti crystalline dystrophy patients with CYP4V2 mutations
- PMID: 16186368
- DOI: 10.1167/iovs.05-0378
Characterization of Bietti crystalline dystrophy patients with CYP4V2 mutations
Abstract
Purpose: Mutations of the CYP4V2 gene, a novel family member of the cytochrome P450 genes on chromosome 4q35, have recently been identified in patients with Bietti crystalline dystrophy (BCD). The aim of this study was to investigate the spectrum of mutations in this gene in BCD patients from Singapore, and to characterize their phenotype.
Methods: Nine patients with BCD from six families were recruited into the study. The 11 exons of the CYP4V2 gene were amplified from genomic DNA of patients by polymerase chain reaction and then sequenced. Detailed characterization of the patients' phenotype was performed with fundal photography, visual field testing, fundal fluorescein angiography, and electroretinography (ERG).
Results: Three pathogenic mutations were identified; two mutations, S482X and K386T, were novel and found in three patients. The third mutation, a previously identified 15-bp deletion that included the 3' splice site for exon 7, was found in all nine patients, with six patients carrying the deletion in the homozygous state. Haplotype analysis in patients and controls indicated a founder effect for this deletion mutation in exon 7. Clinical heterogeneity was present in the patients. Compound heterozygotes for the deletion in exon 7 seemed to have more severe disease compared to patients homozygous for the deletion. There was good correlation between clinical stage of disease and ERG changes, but age did not correlate with disease severity.
Conclusions: This study identified novel mutations in the CYP4V2 gene as a cause of BCD. A high carrier frequency for the 15-bp deletion in exon 7 may exist in the Singapore population. Phenotype characterization showed clinical heterogeneity, and age did not correlate with disease severity.
Similar articles
-
Diagnostic and Management Strategies of Bietti Crystalline Dystrophy: Current Perspectives.Clin Ophthalmol. 2023 Mar 24;17:953-967. doi: 10.2147/OPTH.S388292. eCollection 2023. Clin Ophthalmol. 2023. PMID: 36998515 Free PMC article. Review.
-
Novel mutations in the CYP4V2 gene associated with Bietti crystalline corneoretinal dystrophy.Mol Vis. 2005 Sep 12;11:738-43. Mol Vis. 2005. PMID: 16179904
-
Clinical and molecular findings in three Lebanese families with Bietti crystalline dystrophy: report on a novel mutation.Mol Vis. 2012;18:1182-8. Epub 2012 May 5. Mol Vis. 2012. PMID: 22605929 Free PMC article.
-
Genotype phenotype analysis of Bietti's crystalline dystrophy in patients with CYP4V2 mutations.Invest Ophthalmol Vis Sci. 2007 Nov;48(11):5212-20. doi: 10.1167/iovs.07-0660. Invest Ophthalmol Vis Sci. 2007. PMID: 17962476
-
[Progress in the studies of molecular genetics in Bietti crystalline corneoretinal dystrophy].Zhonghua Yan Ke Za Zhi. 2012 Oct;48(10):948-51. Zhonghua Yan Ke Za Zhi. 2012. PMID: 23302251 Review. Chinese.
Cited by
-
Diagnostic and Management Strategies of Bietti Crystalline Dystrophy: Current Perspectives.Clin Ophthalmol. 2023 Mar 24;17:953-967. doi: 10.2147/OPTH.S388292. eCollection 2023. Clin Ophthalmol. 2023. PMID: 36998515 Free PMC article. Review.
-
Detailed functional and structural phenotype of Bietti crystalline dystrophy associated with mutations in CYP4V2 complicated by choroidal neovascularization.Ophthalmic Genet. 2016 Dec;37(4):445-452. doi: 10.3109/13816810.2015.1126616. Epub 2016 Mar 30. Ophthalmic Genet. 2016. PMID: 27028354 Free PMC article.
-
DISCREPANCY BETWEEN FUNDUS AUTOFLUORESCENCE ABNORMALITY AND VISUAL FIELD LOSS IN BIETTI CRYSTALLINE DYSTROPHY.Retina. 2024 Aug 1;44(8):1394-1402. doi: 10.1097/IAE.0000000000004114. Retina. 2024. PMID: 39047130 Free PMC article.
-
Bietti's crystalline dystrophy in Asians: clinical, angiographic and electrophysiological characteristics.Int Ophthalmol. 2009 Dec;29(6):459-70. doi: 10.1007/s10792-008-9266-7. Epub 2008 Oct 15. Int Ophthalmol. 2009. PMID: 18854949
-
Ocular cytochrome P450s and transporters: roles in disease and endobiotic and xenobiotic disposition.Drug Metab Rev. 2014 Aug;46(3):247-60. doi: 10.3109/03602532.2014.921190. Epub 2014 May 26. Drug Metab Rev. 2014. PMID: 24856391 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources